Rezolute is a late-stage biotechnology company dedicated to improving the lives of individuals affected by rare diseases, particularly those suffering from hypoglycemia due to hyperinsulinism. With a focus on innovative antibody therapies, such as RZ358, Rezolute aims to provide effective treatments for various forms of hyperinsulinism, including congenital and tumor-related cases. The company emphasizes patient engagement and advocacy, ensuring that the voices of patients and caregivers are integral to its strategies and clinical programs. By fostering strong relationships within the rare disease community and prioritizing patient-centric initiatives, Rezolute is committed to enhancing patient outcomes and access to its groundbreaking therapies.